At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MYNZ Mainz Biomed B.V.
Not Yet Opened 11-14 16:00:00 EST
0.2500
+0.0000
0.00%
盘后0.2500
+0.00000.00%
19:59 EST
High0.2600Low0.2240Vol4.79M
Open0.2570D1 Closing0.2500Amplitude14.40%
Mkt Cap6.40MTradable Cap5.52MTotal Shares25.59M
T/O1.16MT/O Rate21.70%Tradable Shares22.09M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
The Oncology Bet Is Already Paying Off For Pfizer
Benzinga  ·  11-14 08:23
The Oncology Bet Is Already Paying Off For Pfizer
Mainz Biomed Partners with Thermo Fisher for Cancer Screening
TIPRANKS  ·  11-12 23:39
Mainz Biomed Partners with Thermo Fisher for Cancer Screening
Mainz Biomed, Thermo Fisher Partner to Develop Colorectal Cancer Screening Test
MT Newswires Live  ·  11-12 22:54
Mainz Biomed, Thermo Fisher Partner to Develop Colorectal Cancer Screening Test
Mainz Biomed, Thermo Fisher sign collaboration agreement
TIPRANKS  ·  11-12 22:15
Mainz Biomed, Thermo Fisher sign collaboration agreement
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
GlobeNewswire  ·  11-12 22:00
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
Mainz Biomed NV expected to post a loss of 25 cents a share - Earnings Preview
reuters  ·  11-08
Mainz Biomed NV expected to post a loss of 25 cents a share - Earnings Preview
Mainz Biomed restructured operations, implemented cost reductions
TIPRANKS  ·  10-21
Mainz Biomed restructured operations, implemented cost reductions
Mainz Biomed Reported Revenue Of $0.52M For H1 2024, Up By 4% YoY, EPS Loss Of $(0.49)
Benzinga  ·  10-21
Mainz Biomed Reported Revenue Of $0.52M For H1 2024, Up By 4% YoY, EPS Loss Of $(0.49)
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire  ·  10-21
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Sees Revenue Growth Amid Cost Reductions
TIPRANKS  ·  10-19
Mainz Biomed Sees Revenue Growth Amid Cost Reductions
Mainz Biomed Secures Additional $1.5M Funding
TIPRANKS  ·  10-10
Mainz Biomed Secures Additional $1.5M Funding
Mainz Biomed reports increased demand for enhanced ColoAlert product
TIPRANKS  ·  10-08
Mainz Biomed reports increased demand for enhanced ColoAlert product
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GlobeNewswire  ·  10-08
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Mainz Biomed Executes Convertible Note Agreement
TIPRANKS  ·  10-04
Mainz Biomed Executes Convertible Note Agreement
The Covid Era Tech Promises To Reinvent Cancer Treatment
Benzinga  ·  10-02
The Covid Era Tech Promises To Reinvent Cancer Treatment
Mainz Biomed CEO issues statement on upcoming milestones
TIPRANKS  ·  10-01
Mainz Biomed CEO issues statement on upcoming milestones
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
GlobeNewswire  ·  10-01
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Pfizer Advances On Its Cancer Journey
Benzinga  ·  09-20
Pfizer Advances On Its Cancer Journey
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
GlobeNewswire  ·  09-18
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Expands AI Collaboration With Liquid Biosciences to Include Pancreatic Cancer Test
MT Newswires Live  ·  09-04
Mainz Biomed Expands AI Collaboration With Liquid Biosciences to Include Pancreatic Cancer Test

Introduction

Company Name.
Mainz Biomed B.V.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Issue price:
--